Cas no 13885-20-6 ((13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione)

(13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione structure
13885-20-6 structure
Product Name:(13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione
CAS No:13885-20-6
MF:C18H22O2
MW:270.366085529327
MDL:MFCD12546624
CID:1256463
PubChem ID:45073644
Update Time:2025-07-15

(13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Chemical and Physical Properties

Names and Identifiers

    • (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione
    • (8ξ)-Estra-4,9-diene-3,17-dione
    • Estra-4,9-diene-3,17-dione, (8ξ)-
    • LogP
    • (+/-)-Estra-4,9-diene-3,17-dione
    • (+/-)-Estra-4,9-diene-3,17-dione (Mixture of 2 EnantioMers)
    • (+/-)-Estra-4,9-diene-3,17-dione (Mixture of 2 Enantiomers)
    • 13-METHYL-1,6,7,8,11,12,13,14,15,16-DECAHYDRO-2H-CYCLOPENTA[A]PHENANTHRENE-3,17-DIONE
    • (8S,13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione
    • (+/-)-19-Norandrosta-4,9-dien-3,17-dione
    • (S)-13-Methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17-dione
    • (3aS,11aS)-11a-methyl-1H,2H,3H,3aH,3bH,4H,5H,7H,8H,9H,10H,11H,11aH-cyclopenta[a]phenanthrene-1,7-dione
    • MFCD12546624
    • AKOS017343733
    • 13885-20-6
    • (3aS,11aS)-11a-methyl-2H,3H,3aH,3bH,4H,5H,8H,9H,10H,11H-cyclopenta[a]phenanthrene-1,7-dione
    • MDL： MFCD12546624
    • Inchi： 1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h10,15-16H,2-9H2,1H3/t15?,16-,18-/m0/s1
    • InChI Key： BHTWZQKERRCPRZ-YLGOGADGSA-N
    • SMILES： O=C1CC[C@H]2C3CCC4=CC(CCC4=C3CC[C@@]21C)=O

Computed Properties

  • Exact Mass: 270.16200
  • Monoisotopic Mass: 270.161979940g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 0
  • Hydrogen Bond Acceptor Count: 2
  • Heavy Atom Count: 20
  • Rotatable Bond Count: 0
  • Complexity: 566
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 2
  • Undefined Atom Stereocenter Count : 1
  • Defined Bond Stereocenter Count: 0
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 1.5
  • Topological Polar Surface Area: 34.1?2

Experimental Properties

  • PSA: 34.14000
  • LogP: 3.76150

(13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
abcr
AB465098-1 g
(S)-13-Methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17-dione; .
 13885-20-6
1g
 €79.00 2023-06-15
abcr
AB465098-5 g
(S)-13-Methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17-dione; .
 13885-20-6
5g
 €229.00 2023-06-15
abcr
AB465098-1g
(S)-13-Methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17-dione; .
 13885-20-6
1g
 €79.00 2025-02-27
abcr
AB465098-5g
(S)-13-Methyl-1,6,7,8,11,12,13,14,15,16-decahydro-2H-cyclopenta[a]phenanthrene-3,17-dione; .
 13885-20-6
5g
 €229.00 2025-02-27

(13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione Related Literature

Related Categories

Additional information on (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione

Recent Advances in the Study of (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione (CAS: 13885-20-6)

The compound (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione (CAS: 13885-20-6) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This research briefing aims to provide a comprehensive overview of the latest findings related to this compound, including its synthesis, biological activity, and potential clinical relevance.

Recent studies have focused on the stereospecific synthesis of (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione, highlighting the importance of chiral centers in modulating its biological activity. Advanced spectroscopic techniques, including NMR and X-ray crystallography, have been employed to confirm the absolute configuration of the compound, ensuring the accuracy of subsequent biological evaluations.

In vitro and in vivo studies have demonstrated that this compound exhibits potent anti-inflammatory and anti-proliferative properties. Mechanistic investigations suggest that it acts through the modulation of key signaling pathways, including the NF-κB and MAPK pathways, which are critical in the regulation of inflammation and cell proliferation. These findings position the compound as a promising candidate for the development of novel therapeutics for inflammatory diseases and certain types of cancer.

Furthermore, recent pharmacokinetic studies have shed light on the compound's bioavailability and metabolic stability. The results indicate that (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione exhibits favorable pharmacokinetic profiles, with good oral bioavailability and moderate half-life, making it suitable for further preclinical development.

Despite these promising findings, challenges remain in optimizing the compound's efficacy and minimizing potential off-target effects. Ongoing research is focused on structural modifications to enhance its selectivity and potency, as well as exploring its potential in combination therapies. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these findings into clinical applications.

In conclusion, (13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione represents a compelling area of research in chemical biology and drug discovery. Its unique structural features, combined with its promising biological activity, make it a valuable candidate for further investigation. Continued research efforts will be crucial in unlocking its full therapeutic potential and addressing the remaining challenges in its development.

13885-20-6 ((13S,14S)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthrene-3,17-dione) Related Products

Recommended suppliers
Shanghai Bent Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
上海嶸奧生物技術(shù)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
上海嶸奧生物技術(shù)有限公司
Jinan Hanyu Chemical Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Jinan Hanyu Chemical Co.,Ltd.
Shenzhen Yaoyuan R&D Center Co.,Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shenzhen Yaoyuan R&D Center Co.,Ltd
Zhangzhou Sinobioway Peptide Co.,Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
Zhangzhou Sinobioway Peptide Co.,Ltd.